MedTrace Logo

To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease

NCT01125683 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-05-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether treatment with single and multiple oral doses of AZD1446 for 1 week will have effect on Quantified Electroencephalography and Event-Related Potentials in patients with Alzheimers Disease. The total treatment period is 9 weeks, divided into 5 equally long sub-periods of 7 days and 4 wash-out periods of 7 days each.

Conditions

  • Alzheimer´s Disease

Interventions

DRUG

AZD1446

Capsule, oral single and multiple dose

DRUG

Donepezil

Capsule, oral and single dose

DRUG

Placebo

Capsule, oral and single dose

Sponsors & Collaborators

Principal Investigators

  • Märta Segerdahl, MD, PhD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Russia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01125683 on ClinicalTrials.gov